Seattle Genetics Begins Phase Ib Study Of SGN-75 Combined With Everolimus NASDAQ (RTTNews.com) - Seattle Genetics Inc. (SGEN) has initiated a phase Ib clinical trial evaluating SGN-75 in combination with everolimus for patients with advanced metastatic renal cell carcinoma or RCC. The study is designed to assess the safety and ... |
